ONCOLOGY TRAINING PROGRAMS FOR SITE STAFF CONDUCTING CLINICAL RESEARCH
These clinical research training courses have been created by the Clinical Imaging Team at Merck Research Laboratories to support understanding of response evaluation criteria in solid tumors (RECIST1) and response evaluation criteria in clinical trials with immunotherapies (iRECIST2):
Recognition or acceptance of course completion may vary by clinical trial sponsor.
NOTE: Take a screenshot of your successful course completion certificate. Your results are NOT recorded.
1 Eisenhauer EA 2009 ‘New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)’ EJC 45: 228-247
2 Seymour L 2017 ‘iRECIST: guidelines for response criteria for use in trials testing immunotherapies’, Lancet Oncology 18: e143-52).
**Take a screenshot of your successful course completion certificate. Your test results are not recorded.**
Please complete the form below for access to RECIST Training Modules
The Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 is the most commonly used method for evaluating changes in tumor burden over time during an oncology clinical trial, and deciding whether the trial participant showed a favorable treatment response or treatment failure. It is used in most malignancies other than hematological malignancies, and has been the basis for numerous regulatory approvals. This course will explain the basic concepts and the detailed steps involved in turning assessments of medical imaging scans into clinical trial endpoints.
This modification of the Response Evaluation Criteria In Solid Tumors (RECIST), published in 2017, is tailored to clinical trials involving cancer immunotherapy, which sometimes causes atypical patterns of treatment response not accounted for by traditional RECIST criteria. This course starts with an assumption that the student already has a strong foundation in RECIST 1.1, and discusses the background for the modified criteria and the process of applying them to evaluating tumor changes in trial participants who appear to exhibit radiographic disease progression.